Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Jaemin Kim, BS"'
Autor:
Jaemin Kim, BS, Youngjoo Lee, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100600- (2023)
Amivantamab is the first drug approved in EGFR exon 20 insertion-mutated NSCLC. Nevertheless, primary or secondary resistance to amivantamab is a frequent problem in clinical practice. We report a case of a patient with EGFR exon 20-mutated NSCLC who
Externí odkaz:
https://doaj.org/article/7248c4d142d545b5b6b62b07b946ca1d